Summary

The 7 major critical limb ischemia markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.21% during 2024-2034.

The critical limb ischemia market has been comprehensively analyzed in IMARC's new report titled "Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Critical limb ischemia (CLI) is a severe form of peripheral arterial disease (PAD) that occurs when there is a significant narrowing or blockage of the arteries that carry blood to the legs and feet. It is a progressive condition that can cause tissue damage, chronic pain, and non-healing wounds, as well as lead to amputation of the affected limb. The most typical symptoms of this disorder include intense foot or leg pain, smooth, hairless, shiny, or very dry feet, skin discoloration, discharge from gangrene, thick toenails, slow-healing sores, weak pulse in the legs or feet, etc. Individuals suffering from CLI may also experience cold hands, feet, or legs, skin infections, loss of muscle mass, fainting, and femoral bruit. The diagnosis of this ailment is based on a review of the patient's symptoms and other medical problems. Some of the common investigations to confirm a diagnosis and stage disease severity include computerized tomography scans, magnetic resonance imaging studies, an ankle-brachial index test, angiograms, doppler ultrasounds, etc. The healthcare provider may also perform Buerger's test to assess arterial sufficiency among patients.

The rising cases of hyperlipidemia due to high cholesterol levels, which cause narrowed or blocked arteries, are primarily driving the critical limb ischemia market. In addition to this, the elevating incidences of several associated risk factors, including smoking, sedentary lifestyles, high blood pressure, obesity, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as beta-blockers, antiplatelet drugs, statins, etc., to prevent clots, control cholesterol levels, decrease blood pressure, and improve blood flow is also creating a positive outlook for the market. Apart from this, the widespread adoption of the pedal-plantar loop technique for percutaneous revascularization of the foot arteries, since it can facilitate better inflow and outflow from both posterior and anterior tibial vessels, is further bolstering the market growth. Additionally, the escalating utilization of intermittent pneumatic compression devices to reduce resting pain, as well as improve healing rates and physical functions in patients unsuitable for amputation, is acting as another significant growth-inducing factor. Besides this, the rising usage of stem cell-based therapy, which prolongs limb survival, decreases the speed of symptom progression, and enhances the quality of life, is expected to drive the critical limb ischemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the critical limb ischemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for critical limb ischemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the critical limb ischemia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the critical limb ischemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the critical limb ischemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current critical limb ischemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the critical limb ischemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the critical limb ischemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the critical limb ischemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of critical limb ischemia across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of critical limb ischemia by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of critical limb ischemia by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with critical limb ischemia across the seven major markets?
What is the size of the critical limb ischemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of critical limb ischemia?
What will be the growth rate of patients across the seven major markets?

Critical Limb Ischemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for critical limb ischemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the critical limb ischemia market?
What are the key regulatory events related to the critical limb ischemia market?
What is the structure of clinical trial landscape by status related to the critical limb ischemia market?
What is the structure of clinical trial landscape by phase related to the critical limb ischemia market?
What is the structure of clinical trial landscape by route of administration related to the critical limb ischemia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Critical Limb Ischemia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Critical Limb Ischemia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Critical Limb Ischemia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Critical Limb Ischemia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Critical Limb Ischemia - Unmet Needs

10 Critical Limb Ischemia - Key Endpoints of Treatment

11 Critical Limb Ischemia - Marketed Products
11.1 List of Critical Limb Ischemia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Critical Limb Ischemia - Pipeline Drugs
12.1 List of Critical Limb Ischemia Pipeline Drugs Across the Top 7 Markets
12.1.1 YQ23 - New Beta Innovation
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ASCT 01 - Lifecells LLC
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CLBS12 - Lisata Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ACP 01 - Hemostemix
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 REX-001 - Rexgenero
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Critical Limb Ischemia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Critical Limb Ischemia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Critical Limb Ischemia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Critical Limb Ischemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Critical Limb Ischemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Critical Limb Ischemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Critical Limb Ischemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Critical Limb Ischemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Critical Limb Ischemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Critical Limb Ischemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Critical Limb Ischemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Critical Limb Ischemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Critical Limb Ischemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Critical Limb Ischemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Critical Limb Ischemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Critical Limb Ischemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Critical Limb Ischemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Critical Limb Ischemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Critical Limb Ischemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Critical Limb Ischemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Critical Limb Ischemia - Access and Reimbursement Overview

16 Critical Limb Ischemia - Recent Events and Inputs From Key Opinion Leaders

17 Critical Limb Ischemia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Critical Limb Ischemia Market – Strategic Recommendations

19 Appendix